Skip to main content
. 2025 May 6;10(5):105058. doi: 10.1016/j.esmoop.2025.105058

Figure 5.

Figure 5

Kaplan-Meier plots of overall survival by treatment arm and tissue TMB high/low status. OS in tTMB (A) ≥10 and <10, (B) ≥13 and <13, and (C) ≥16 and <16 mut/Mb subgroups for T + D + CT versus CT and D + CT versus CT. Data cut-off: 12 March 2021. HR and CI were estimated from an unstratified Cox proportional hazards model. CI, confidence interval; CT, chemotherapy; D, durvalumab; HR, hazard ratio; Mb, megabase; mOS, median OS, mut, mutations; NE, not estimable; OS, overall survival; T, tremelimumab; tTMB, tissue tumor mutational burden.